However, given the highly varied responses in patients receiving these medications, these and other biomarkers warrant continued exploration, particularly for cancers in which better-established methods such as PD-L1 expression and TMB fail to reliably predict for patients most likely to derive clinical benefit from ICI-based immunotherapy. This evidence concerns the gene CD274 and cancer.